This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FMTX Forma Therapeutics (FMTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Forma Therapeutics Stock (NASDAQ:FMTX) 30 days 90 days 365 days Advanced Chart Get Forma Therapeutics alerts:Sign Up Key Stats Today's Range$20.01▼$20.0150-Day Range$19.91▼$20.0152-Week Range$4.95▼$20.68Volume1 shsAverage Volume847,595 shsMarket Capitalization$957.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Read More… Receive FMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FMTX Stock News HeadlinesForma Therapeutics Holdings, Inc. (FMTX)September 25, 2022 | finance.yahoo.comBiotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & MoreSeptember 7, 2022 | finance.yahoo.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.April 26, 2025 | Brownstone Research (Ad)SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates GMTX, FMTX, SGFY, ECOMSeptember 7, 2022 | apnews.comThe M&A Class Action Firm Announces the Investigation of Forma Therapeutics Holdings, Inc. - FMTXSeptember 7, 2022 | benzinga.com4 Analysts Have This to Say About Forma Therapeutics HldgsSeptember 2, 2022 | markets.businessinsider.comForma Therapeutics: Rare Disease PlaySeptember 2, 2022 | seekingalpha.comNovo Nordisk To Acquire Forma Therapeutics - Quick FactsSeptember 1, 2022 | markets.businessinsider.comSee More Headlines FMTX Stock Analysis - Frequently Asked Questions How were Forma Therapeutics' earnings last quarter? Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.05. When did Forma Therapeutics IPO? Forma Therapeutics (FMTX) raised $201 million in an IPO on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse served as the underwriters for the IPO. What other stocks do shareholders of Forma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forma Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Cheniere Energy (LNG), Netflix (NFLX), Marvell Technology (MRVL) and Viper Energy (VNOM). Company Calendar Last Earnings11/12/2021Today4/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FMTX CIK1538927 Webwww.formatherapeutics.com Phone617-679-1970FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-172,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.68% Return on Assets-35.33% Debt Debt-to-Equity RatioN/A Current Ratio12.74 Quick Ratio12.74 Sales & Book Value Annual Sales$100.56 million Price / Sales9.52 Cash FlowN/A Price / Cash FlowN/A Book Value$10.51 per share Price / Book1.90Miscellaneous Outstanding Shares47,853,000Free Float45,082,000Market Cap$957.54 million OptionableNot Optionable Beta-0.94 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:FMTX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forma Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.